Century Communities Sets Date for Third Quarter 2026 Earnings Release and Conference Call
Image File
Original HTML

GREENWOOD VILLAGE, Colo., Oct. 6, 2026 /PRNewswire/ -- Century Communities, Inc. (NYSE: CCS), a leading national homebuilder, today announced that the Company will release its third quarter 2026 financial results after the market closes on Wednesday, October 28, 2026. A conference call will be held that same day at 5:00 p.m. Eastern time, 3:00 p.m. Mountain time, to review the Company's third quarter results, discuss recent events and conduct a question-and-answer session.

Webcast:

The conference call will be available in the Investors section of the Company's website at www.centurycommunities.com. To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time in order to register, download and install any necessary audio software.

To Participate in the Telephone Conference Call:

Dial in at least 5 minutes prior to start time

Domestic: 1-833-461-5787

International: 1-585-542-9983

Conference ID: 100 064 380

About Century Communities:

Century Communities, Inc. (NYSE: CCS) is one of the nation's largest homebuilders and a recognized industry leader in online home sales. Newsweek has named the Company one of America's Most Trustworthy Companies for four consecutive years. Century Communities has also been designated as one of U.S. News & World Report's Best Companies to Work For (2025–2026). Through its Century Communities and Century Complete brands, Century's mission is to build attractive, high-quality homes at affordable prices to provide its valued customers with A HOME FOR EVERY DREAM®. Century is engaged in all aspects of homebuilding — including the acquisition, entitlement and development of land, along with the construction, innovative marketing and sale of quality homes designed to appeal to a wide range of homebuyers. The Company operates in 16 states and over 45 markets across the U.S., and also offers mortgage, title, insurance brokerage, and escrow services in select markets through its Inspire Home Loans, Parkway Title, IHL Home Insurance Agency, and IHL Escrow subsidiaries. To learn more about Century Communities, please visit www.centurycommunities.com.

Contact Information:

Tyler Langton

Senior Vice President, Investor Relations and Finance

303-268-8345

[email protected]

SOURCE Century Communities, Inc.

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Need Review
Dedupe hash
prn_302900154
Press Eligible
Yes
Press Eligible Reason
QA FAIL (need review): Final paragraph is a generic 'About the Company' boilerplate (company description, brands, services) with no news context, copied/condensed from the source's boilerplate.
Source Name
Unknown Company
Original Summary

<p>GREENWOOD VILLAGE, Colo., Oct. 6, 2026 /PRNewswire/ -- Century Communities, Inc. (NYSE: CCS), a leading national homebuilder, today announced that the Company will release its third quarter 2026 financial results after the market closes on Wednesday, October 28, 2026. A conference call...</p>

Image URL
https://mmx.prnewswire.com/media/MS964860/Century-Communities-Logo-v1.jpg?id=OA2990206&p=facebook
Generated Article_json
{"target_audience": "b2b", "is_medical": false, "ai_generated_title": "Century Communities to Report Q3 2026 Earnings Oct. 28", "body_html": "<p><strong>Greenwood Village, Colo. -- [CURRENT_DATE] --</strong> Century Communities, Inc. (NYSE: CCS) will release its third quarter 2026 financial results after market close on Wednesday, October 28, 2026.</p><h5>Company sets conference call for 5:00 p.m. Eastern on earnings day</h5><p>The national homebuilder will host a conference call the same day at 5:00 p.m. Eastern time (3:00 p.m. Mountain time) to review third-quarter results, discuss recent developments and take analyst questions.</p><h5>Investors can access results via webcast or telephone dial-in</h5><p>A live webcast will be available through the Investors section of the Company's website, with registration recommended at least 15 minutes before the scheduled start. Telephone participants can dial a domestic number (1-833-461-5787) or international number (1-585-542-9983) using Conference ID 100 064 380, with dial-in advised at least five minutes prior to the call.</p><h5>Century Communities operates across 16 states, over 45 U.S. markets</h5><p>The homebuilder runs operations through its Century Communities and Century Complete brands, covering land acquisition, entitlement, development, construction and sales. It also provides mortgage, title, insurance brokerage and escrow services in select markets via subsidiaries Inspire Home Loans, Parkway Title, IHL Home Insurance Agency and IHL Escrow.</p>", "meta_description": "Century Communities (NYSE: CCS) will report Q3 2026 earnings Oct. 28 after market close, followed by a 5 p.m. ET conference call for investors.", "seo_keywords": "Century Communities, CCS earnings, Q3 2026 results, homebuilder, conference call, NYSE CCS, investor relations", "companies": ["Century Communities, Inc."], "industries": ["Construction & Infrastructure"], "markets_regions": ["United States"], "news_type": ["financial_disclosure"], "themes": ["general"], "products": [], "events": ["Q3 2026 Earnings Call"], "cta_text": "Join the conference call on October 28, 2026 to hear Century Communities' third quarter 2026 results.", "learn_more": "https://www.centurycommunities.com", "fact_check": {"accuracy_score": 100, "legal_risk": "low", "corrections_made": [], "recommendation": "publish"}}
Content Hash (SHA-256, erste 32 hex)
8ed4d4c4c62e3f862f49b65eae20cc53
Symplr software (symplr®), Announces Strategic Refinancing Transaction to Strengthen Financial Position and Support Long-Term Growth
Image File
Original HTML

Transaction extends key debt maturities and provides approximately $280 million of new capital to support continued investment and growth

HOUSTON, Oct. 6, 2026 /PRNewswire/ -- symplr®, a leading provider of enterprise healthcare operations software, today announced that it has secured commitment letters for a comprehensive refinancing transaction to strengthen the company's capital structure, enhance liquidity, and support the continued execution of its long-term growth strategy. The transaction is expected to close by the end of October.

The transaction will extend the maturity of symplr's first-lien term loan and revolving credit facility to December 2030 and the maturity of its second-lien term loans to June 2031. The refinancing will provide approximately $280 million of new capital, including a substantial new investment from symplr's sponsors, Clearlake Capital Group and Charlesbank Capital Partners.

The extended maturities and new capital will enhance symplr's liquidity, reduce near-term cash interest requirements and provide the company with greater financial flexibility. Together, the new capital and extended maturity profile will give symplr additional time and resources to execute its strategy, invest in the business and continue delivering value for its customers.

"This transaction is an important step forward for symplr and positions us well for the future," said Venkat Kavarthapu, Chief Executive Officer of symplr. "By extending our debt maturities and bringing substantial new capital into the business, we are creating greater financial flexibility and additional runway to execute our strategy. The continued investment from Clearlake and Charlesbank, together with the broad support of our lenders, reflects confidence in symplr, our team and the opportunity ahead."

The transaction has the full support of Clearlake and Charlesbank, as well as symplr's lender groups.

Following completion of the transaction, symplr will remain focused on serving its customers, advancing its healthcare operations platform, and executing against its strategic priorities.

About symplr

symplr is a leader in enterprise healthcare operations software and services with a first-of-its-kind operations platform. Trusted in 9 of 10 U.S. hospitals and 400+ U.S. health plans, symplr optimizes operations and maximizes care powered by our cloud-based workforce, quality, provider data management, and spend solutions. Gain efficiency, reduce complexity, and improve outcomes where it matters most. Learn how to stay ahead of change at www.symplr.com.

Contact:

Sean Chase

[email protected]

617-275-6531

SOURCE symplr

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Rewritten
Dedupe hash
prn_302900252
Press Eligible
Yes
Press Eligible Reason
Healthcare software company announces a strategic refinancing and new capital to support growth.
Source Name
Unknown Company
Original Summary

<p>Transaction extends key debt maturities and provides approximately $280 million of new capital to support continued investment and growth HOUSTON, Oct. 6, 2026 /PRNewswire/ -- symplr®, a leading provider of enterprise healthcare operations software, today announced that it has secured...</p>

Image URL
https://mmx.prnewswire.com/media/MS1114938/symplr-Logo-Logo.jpg?id=OA2990820&p=facebook
Content Hash (SHA-256, erste 32 hex)
4c9b28b0ae470e7ad15b3479dc5410ca
Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology
Image File
Original HTML

Expanded agreement increases argenx's exclusive access to ENHANZE® from six to eight targets

SAN DIEGO, Oct. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced that it has expanded its global collaboration and license agreement with argenx to develop and commercialize ENHANZE® with two additional exclusive targets.

"We are pleased to expand our collaboration with argenx, a recognized leader in immunology, building on the successful development of VYVGART Hytrulo," said Dr. Helen Torley, President and Chief Executive Officer of Halozyme. "The addition of two new exclusive targets further validates the value and versatility of ENHANZE as the leading platform for rapid, large-volume subcutaneous delivery. As more companies seek to focus on patient convenience, reducing treatment burden and expanding access to important therapies, ENHANZE continues to be the technology of choice. This expanded agreement strengthens our growing portfolio of partnered programs and reinforces the significant long-term opportunity for ENHANZE across a broad range of therapeutic areas."

"Our partnership with Halozyme shows what co-creation can do for patients," said Arjen Lemmen, Vice President of Corporate Development and Strategy, argenx. "Together, we brought VYVGART Hytrulo to people living with MG and CIDP, which gave patients a subcutaneous option that fits more easily into their lives. Expanding to two more targets lets us bring that same focus on patient experience to more of our pipeline as we build a broader immunology portfolio. We're proud to keep building on a partnership, rooted in shared ambition and scientific rigor."

Halozyme is eligible to receive payments upon achievement of agreed upon milestones and will receive royalties on net sales of products using ENHANZE®.

About Halozyme

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V., GSK, and Incyte.

Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and Surf Bio's hyperconcentration technology, recently renamed as Aerocon™. Hypercon™ is an innovative microparticle technology expected to set a new standard in hyperconcentration of drugs and biologics by reducing injection volume for the same dosage and enabling administration in at‑home and healthcare‑provider settings. Aerocon's polymer‑based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. Together, Hypercon™ and Aerocon™ complement ENHANZE® by enabling creation and delivery of highly concentrated biologics. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Janssen, Eli Lilly, argenx, Vertex Pharmaceuticals and Oruka Therapeutics.

Halozyme also develops, manufactures and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex® and XYOSTED®, partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.

Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility.

For more information, visit www.halozyme.com and connect with us on LinkedIn.

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning royalty revenue growth, margins and durability, potential new partnerships and innovations, the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs and statements concerning certain other potential benefits of ENHANZE® including facilitating more convenient administration and dosing regimens of injectable medications through subcutaneous delivery and potentially lowering the treatment burden, easing treatment access and improving the treatment experience for patients. These forward-looking statements may also include statements regarding the product development and commercialization efforts of Halozyme's collaboration partner (including the potential advancement, regulatory approval and launch of products as a result of such efforts) and Halozyme's potential future receipt of payments associated with achievement of certain milestones, and royalties on sales of commercialized products. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "expect," "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue" and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including risks and uncertainties concerning whether development, regulatory and sales-based milestones will be achieved, uncertainties concerning whether collaborative products for the two additional targets referred to in this press release are ultimately developed, approved or commercialized and the potential future market for such products, unexpected levels of revenue growth, expenditures and costs, unexpected results or delays in development and regulatory review, unexpected regulatory approval requirements, unexpected adverse events or patient outcomes and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Contact:

Tram Bui

VP, Investor Relations and Corporate Communications

609-333-7668

[email protected]

SOURCE Halozyme Therapeutics, Inc.

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Rewritten
Dedupe hash
prn_302900270
Press Eligible
Yes
Press Eligible Reason
Biopharmaceutical companies expand a technology licensing and development collaboration.
Source Name
Unknown Company
Original Summary

<p>Expanded agreement increases argenx's exclusive access to ENHANZE® from six to eight targets SAN DIEGO, Oct. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced that it has expanded its global collaboration and license agreement...</p>

Image URL
https://mmx.prnewswire.com/media/MS254664/Halozyme-Therapeutics-Logo.jpg?id=OA2990054&p=facebook
Content Hash (SHA-256, erste 32 hex)
6e1bc235fbe9584f9f940403674058c1
Simon® Announces Date For Its Third Quarter 2026 Earnings Release And Conference Call
Image File
Original HTML

INDIANAPOLIS, Oct. 6, 2026 /PRNewswire/ -- Simon®, a real estate investment trust engaged in the ownership of premier shopping, dining, entertainment and mixed-use destinations, today announced details for its third quarter earnings release and conference call.

Simon's financial and operational results for the quarter ending September 30, 2026, will be released after the market close on November 5, 2026. Simon will host its quarterly earnings conference call and an audio webcast on November 5 from 5:00 p.m. to 6:00 p.m. Eastern Time.

The live webcast will be available in listen-only mode at investors.simon.com. Interested parties can join the call by dialing:

- 1-844-826-3035 United States participants

- 1-412-317-5195 Participants outside the United States

- The conference ID for the call is "10212388."

An audio replay will be available from approximately 9:00 p.m. Eastern Time on November 5, 2026 until 11:00 p.m. Eastern Time on November 12, 2026. The replay can be accessed within the United States by dialing 1-844-512-2921. Callers outside the U.S. can access the replay at 1-412-317-6671. The replay passcode is "10212388." The call will also be archived on investors.simon.com for approximately 90 days.

About Simon      

Simon® is a real estate investment trust engaged in the ownership of premier shopping, dining, entertainment and mixed-use destinations (Simon Property Group, NYSE: SPG). Our properties across North America, Europe and Asia provide community gathering places for millions of people every day and generate billions in annual sales.

SOURCE Simon

Share this article

Ingest Status
Rejected
Dedupe hash
prn_302899872
Source Name
Unknown Company
Original Summary

<p>INDIANAPOLIS, Oct. 6, 2026 /PRNewswire/ -- Simon®, a real estate investment trust engaged in the ownership of premier shopping, dining, entertainment and mixed-use destinations, today announced details for its third quarter earnings release and conference call. Simon's financial and...</p>

Image URL
https://mmx.prnewswire.com/media/MS339832/SIMON-Logo-Logo.jpg?id=OA2989811&p=facebook
Content Hash (SHA-256, erste 32 hex)
98e2b59fe6273373bb3e9c1b1ad56eb6
CATCH Greater Houston Wins Two of Ten National Health at Home Challenge Awards
Image File
Original HTML

CATCH Greater Houston Wins Two of Ten National Health at Home Challenge Awards

Recognition brings expanded home-based care to Houstonians covered by both Medicare and Medicaid

HOUSTON, Oct. 6, 2026 /PRNewswire/ -- CATCH Greater Houston is part of two of the ten teams named Phase 1 winners of the Health at Home Challenge, a national competition of the Administration for Community Living (ACL) within the U.S. Department of Health and Human Services. CATCH won as a community care hub within the national consortium led by the Oregon Wellness Network, which spans eight hubs in eight states, and as designated lead of the Texas Hub Network, a statewide consortium formed with the Texas Health and Human Services Commission.

The Challenge supports independence, improves health, and reduces costs for Medicare and Medicaid beneficiaries who are dually eligible or near-dually eligible — older adults and people with disabilities living with multiple chronic conditions and at least one functional limitation. ACL aims to reach up to one million of them nationally through advanced community care networks led by community care hubs.

Both teams advanced to Phase 2, the Implementation Accelerator, running August 2026 through July 2027. ACL will select up to five Phase 2 winners, and only those teams advance to Phase 3 scaling awards in August 2027.

"Houston is not just participating in this work — we are helping lead it. For the people we serve, that means more days at home, fewer trips back to the hospital, and someone whose job it is to make their care make sense. Our founding partners believed in this model first, and our health systems chose to build it with us," said Janice Sparks, Executive Director of CATCH Greater Houston.

What This Means for Greater Houston

CATCH delivers this work with committed health care partners across the region — the Houston Health Department, Memorial Hermann Health System, Harris Health, the CommonSpirit Baylor St. Luke's accountable care organization, and UT Physicians. Hospitals, primary care practices, and health plans refer patients directly to CATCH, which provides the Challenge's five core services: navigation, care coordination and management, care transitions, evidence-based health promotion, and nutrition.

In practice, that means dually eligible and near-dually eligible Houstonians get help returning home safely after a hospital or nursing facility stay, care plans supported by nurses and community health workers, fall prevention and chronic disease programs close to home, and meals delivered to their door.

One Shared Record

All eight hubs in the national consortium will operate on a single shared AthenaOne electronic medical record — a first for community-based care at this scale — with analytics that help care teams identify at-risk individuals earlier and measure what matters: days spent at home and the total cost of care. The UTHealth Houston School of Public Health will independently evaluate outcomes nationwide.

Houston-area residents and families can learn more at www.catchgh.org or call 832-509-6141.

About CATCH Greater Houston

CATCH Greater Houston is a non-profit community care hub founded by the Houston Health Department, the Ibn Sina Foundation, the Houston Health Foundation, and the UTHealth Houston School of Public Health. CATCH organizes community-based organizations across greater Houston to deliver care coordination, care transitions, social-needs screening, and evidence-based health promotion in partnership with the region's hospitals, health systems, and health plans.

The Health at Home Challenge is administered by the Administration for Community Living. This announcement does not imply endorsement by ACL, HHS, or the federal government.

SOURCE CATCH Greater Houston

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Rewritten
Dedupe hash
prn_302900304
Press Eligible
Yes
Press Eligible Reason
Healthcare organization and partners advance a community-based care initiative through a national challenge.
Source Name
Unknown Company
Original Summary

<p>Recognition brings expanded home-based care to Houstonians covered by both Medicare and Medicaid HOUSTON, Oct. 6, 2026 /PRNewswire/ -- CATCH Greater Houston is part of two of the ten teams named Phase 1 winners of the Health at Home Challenge, a national competition of the Administration...</p>

Image URL
https://catchgh.org/wp-content/uploads/elementor/thumbs/ibn-sina-foundation-r0efeoq9ro2ld18btxwl4cbqloxq9xs8bp1n2wt2hc.webp
Content Hash (SHA-256, erste 32 hex)
404fcf78e815705c20d091cff0d63515
Boston Green Company Appoints Dmitro Popovich as Director of Business Development - Terminal, Marine &amp; Industrial Services
Image File
Original HTML

LAKEVILLE, Mass., Oct. 6, 2026 /PRNewswire/ -- Boston Green Company, a leading provider of environmental and material handling solutions, today announced the appointment of Dmitro Popovich as Director of Business Development – Terminal, Marine & Industrial Services. In this role, he will lead growth efforts and build client partnerships with terminal, marine, and industrial operators across the Northeast.

Popovich brings more than 18 years of experience in bulk liquid and dry bulk marine terminal operations. His background covers petroleum and third-party cargo handling, safety and environmental compliance, capital planning, and maintenance coordination. That hands-on experience gives him a clear view of the regulatory, safety, and operational pressures terminal and industrial clients face every day.

Before joining Boston Green Company, Popovich served as Director of Operations at Sprague Operating Resources LLC. In that role, he oversaw bulk liquid and dry bulk operations at five terminals in New Hampshire and Maine, led and mentored more than 100 terminal personnel and site leaders, and managed annual operating budgets exceeding $30 million. He also coordinated more than $5 million in capital projects each year and partnered with HSE teams, regulators, and emergency management organizations on compliance and emergency preparedness programs.

Popovich built his career from the ground up. He started as an operator in Everett, Massachusetts, in 2008 and advanced through terminal supervisor and terminal manager roles in New York, Massachusetts, and New Hampshire. He holds a Bachelor of Science in Automotive Technology, with a minor in Business Management, from Benjamin Franklin Institute of Technology in Boston.

"Dmitro brings a level of firsthand operational expertise that is rare in business development," said Adam Dennison, CEO of Boston Green Company. "He has managed the exact challenges our terminal, marine, and industrial clients face every day — from regulatory compliance and emergency preparedness to large-scale capital programs. That experience translates directly into better solutions for our clients, and we are thrilled to have him leading this important growth area for our company."

Popovich expressed equal enthusiasm for the opportunity. "Boston Green's commitment to safety, compliance, and delivering real results for clients aligns perfectly with the way I've approached my entire career," said Popovich. "I look forward to working alongside their team to help terminal operators, marine facilities, and industrial clients build smarter, more sustainable environmental programs that keep their operations running safely and efficiently."

In his new position, Popovich will work closely with terminal operators, marine facilities, and industrial clients to design customized environmental and material handling programs. He will focus on strengthening Boston Green Company's presence in the terminal and marine sectors while delivering the responsive, reliable service the company is known for.

For more information about services or to schedule a consultation, please contact Boston Green Company at 866-338-3967 or visit their website at www.bostongreencompany.com.

SOURCE Boston Green Company

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Rewritten
Dedupe hash
prn_302900256
Press Eligible
Yes
Press Eligible Reason
Company leadership appointment and business development news in environmental and industrial services.
Source Name
Unknown Company
Original Summary

<p>LAKEVILLE, Mass., Oct. 6, 2026 /PRNewswire/ -- Boston Green Company, a leading provider of environmental and material handling solutions, today announced the appointment of Dmitro Popovich as Director of Business Development – Terminal, Marine & Industrial Services. In this role, he will...</p>

Image URL
https://mmx.prnewswire.com/media/MS2003369/00000_Dmitro_Popovich_blast_art.jpg?id=OA2990075&p=facebook
Content Hash (SHA-256, erste 32 hex)
2f6ed69e6480b9fcef93045b42579ef9
Cibola County Commissioners Support In-Situ Recovery of Uranium Technology
Image File
Original HTML

GRANTS, NEW MEXICO, Oct. 6, 2026 /PRNewswire/ -- The Clean Energy Association of New Mexico (CLEAN) today congratulates the Cibola County Board of Commissioners which, through a County resolution, recognized the strategic importance of the Grants Mineral Belt and In-Situ Recovery ("ISR") for uranium extraction. CLEAN also acknowledges the leadership of the Cibola County Board of Commissioners in voting to approve the resolution.

CLEAN President, Janet Lee-Sheriff, stated "Addressing historic legacy issues has always been a key message from CLEAN as we move forward with environmentally-responsible solutions to extract naturally-occurring uranium from contaminated sources. The support of local citizens and their elected officials is critical and CLEAN greatly appreciates the research conducted by Cibola County officials and staff to make an informed decision based on sound information. ISR uranium extraction has the potential to safely remove uranium without tailings or underground workings, while bringing economic benefits to the State, communities and its citizens."

As ISR projects move forward, State and federal regulators oversee a highly regulated process that allows for public comment on all projects. Necessary independent research and analysis is gathered and reviewed by regulatory agencies with public forums convened to ensure citizens are provided with necessary information for good decision-making. Decisions, such as the support of the Cibola County Board of Commissioners are important as they allow for thorough, balanced and complete information to be presented to the regulators and public.

About In-Situ Recovery Technology

In-Situ Recovery ("ISR") was developed in the United States over 50 years ago and is responsible for approximately 60% of all uranium extraction in the world. ISR offers a minimally intrusive, eco-friendly, and economically competitive approach to mineral extraction successfully utilized in Texas, Nebraska, Wyoming as well as numerous locations globally. Unlike traditional mining, ISR utilizes wellfield technology to extract uranium from ISR-amenable, sandstone-hosted deposits, eliminating the need for open pits, underground working and tailings. The nuclear energy industry is the most highly regulated industry in the United States and the Nuclear Regulatory Commission has stated that there has never been an incident of the contamination of drinking water from the ISR process.1

About the Clean Energy Association of New Mexico

The Clean Energy Association of New Mexico (CLEAN) provides education, awareness, and innovative tools to support a strong and safe nuclear energy sector needed to fuel the U.S. nuclear renaissance. CLEAN advocates for responsible uranium extraction and recovery through In-Situ Recovery ("ISR"), working to build sustainable socio-economic benefits for local communities and the State while respecting the land, water, air, and people. CLEAN hosted the inaugural Nuclear in New Mexico conference in April 2026 and will host the 2nd annual conference in May 2027.

SOURCE Clean Energy Association of New Mexico

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Rewritten
Dedupe hash
prn_302900260
Press Eligible
Yes
Press Eligible Reason
Energy-sector news about county support for uranium extraction technology.
Source Name
Unknown Company
Original Summary

<p>GRANTS, NEW MEXICO, Oct. 6, 2026 /PRNewswire/ -- The Clean Energy Association of New Mexico (CLEAN) today congratulates the Cibola County Board of Commissioners which, through a County resolution, recognized the strategic importance of the Grants Mineral Belt and In-Situ Recovery ("ISR")...</p>

Image URL
https://mmx.prnewswire.com/media/MS1994597/Clean-Energy-Association-of-New-Mexico-Cibola-County-Commissione.jpg?id=OA2990996&p=facebook
Content Hash (SHA-256, erste 32 hex)
da15df1d1188e31377ccd367626ce242
Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors
Image File
Original HTML

REHOVOT, Israel, Oct. 6, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneer in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced that it has entered into a comprehensive cooperation agreement (the "Agreement") with L.I.A. Pure Capital Ltd. and Invest Pro Shukai Hon Ltd. (together, the "Pure Capital Group") to resolve all outstanding differences between the parties. The agreement is intended to establish long-term operational stability and empower Evogene to focus entirely on its goal of becoming a world leader in AI-driven small-molecule discovery and optimization for the pharmaceutical and ag-chemical industries.

Subsequent to the Annual General Meeting of Evogene convened on September 4, 2026 (the "Meeting"), the Pure Capital Group asserted various claims concerning the voting results of the Meeting, as published by the Company in its Report of Foreign Private Issuer on Form 6-K dated September 4, 2026. Furthermore, on September 8, 2026, the Pure Capital Group served notice to the Company of its intention to initiate a special tender offer pursuant to Section 328 of the Israeli Companies Law, 5759-1999 (the "Companies Law").

Following constructive negotiations and discussions, Evogene and the Pure Capital Group reached an agreement that the Board of Directors of the Company (the "Board") unanimously determined to be in the best interests of the Company and its shareholders. The Agreement resolves all disputes, avoids a prolonged, disruptive, and expensive legal process, and affords the Company the stability to continue advancing its current business strategy, commercial collaborations, and technology development centered on ChemPass AI™.

Key Terms of the Cooperation Agreement

Under the terms of the Agreement, two current directors, Dr. Yael Margolin and Mr. Yoshinori Oikawa, who resigned from the Board will be replaced by Pure Capital Group nominees Dr. Adi Zuluf-Shani and Mr. Oz Adler. Promptly following execution, the Company will convene a general meeting of shareholders, to be held no later than forty-two (42) days following execution, to elect Dr. Zuluf-Shani and Mr. Adler as directors to the Board, to approve the Agreement, including the mutual waivers and releases and mutual non-disparagement covenants set forth therein, and, subject to such approval, to approve the election of two additional Pure Capital Group nominees, Mr. Itay Maroz and Mr. Shahar Zadok, in place of outgoing directors Mr. Dan Falk and Dr. Adrian Percy. Following shareholder approval, the reconstituted Board will comprise seven directors, including four nominated by the Pure Capital Group and three continuing directors (Mr. Ofer Haviv, Mr. Nir Nimrodi, and Mr. Leon Y. Recanati) who will serve during a transition period currently expected to be up to six months, unless otherwise agreed by the Board in consultation with the Pure Capital Group. Following that transition period, if any continuing director has not tendered his resignation from the Board, the Board may convene a general meeting of shareholders to remove that continuing director. In addition, the Pure Capital Group has agreed to formally withdraw its notice regarding the special tender offer and enter into a 60-day standstill period, during which the Company has also agreed to refrain from issuing shares or convertible securities, including through its at-the-market facility, other than issuances to employees in the ordinary course of business and in line with prior business practice.

About Evogene:

Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for drug development and ag-chemical products. At the core of its technology is ChemPass AI™, a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries, driven by the integration of scientific innovation with real-world industry needs.

For more information, please visit www.evogene.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to future events. These statements may be identified by words such as "may," "could," "expects," "hopes," "intends," "anticipates," "plans," "believes," "scheduled," "estimates," "demonstrates," "designed to," "intended to," "with the goal of," or words of similar meaning. For example, Evogene uses forward-looking statements in this press release when it discusses the convening of a special general meeting of shareholders, the contemplated changes to the composition of its Board of Directors, the anticipated transition period, the expected benefits of the cooperation agreement, and the continuation and advancement of the Company's business strategy. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the aftermath of the recent wars between Israel and each of (i) the terrorist groups Hamas and Hezbollah, (ii) Iran, and (iii) other regional terrorist groups supported by Iran, and any potential destabilizations in Israel, neighboring territories or the Middle East region, and those additional risk factors contained in Evogene's reports filed with the applicable securities authority. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their preclinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Forward-looking statements speak only as of the date of this press release. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions, except as required by applicable law.

Investor Relations Contact:

[email protected]

Tel: +972-8-9311901

SOURCE Evogene

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Need Review
Dedupe hash
prn_302900213
Press Eligible
Yes
Press Eligible Reason
QA FAIL (need review): TARGET incorrectly states the board will 'expand to seven directors,' whereas the SOURCE describes a reconstituted board of seven with no expansion; it also adds the unsupported characterization 'hostile tender offer,' which is not present in the SOURCE.
Source Name
Unknown Company
Original Summary

<p>REHOVOT, Israel, Oct. 6, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneer in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced that it has entered into a...</p>

Image URL
https://mmx.prnewswire.com/media/MS1751115/Evogene-Logo.jpg?id=OA2990154&p=facebook
Generated Article_json
{"target_audience": "b2b", "is_medical": false, "ai_generated_title": "Evogene Settles Board Dispute With Pure Capital Group, Averts Tender Offer", "body_html": "<p><strong>Rehovot -- [CURRENT_DATE] --</strong> Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) has signed a comprehensive cooperation agreement with L.I.A. Pure Capital Ltd. and Invest Pro Shukai Hon Ltd. (together, the \"Pure Capital Group\") to resolve a governance dispute that had threatened a hostile tender offer under Israeli securities law.</p><h5>Dispute followed contested September 4 annual meeting vote</h5><p>The conflict emerged after Evogene's Annual General Meeting on September 4, 2026, when the Pure Capital Group disputed the voting results disclosed in the company's Form 6-K filing. On September 8, 2026, the group notified Evogene of its intent to launch a special tender offer under Section 328 of the Israeli Companies Law, 5759-1999, a move that could have disrupted the company's operations and triggered costly litigation.</p><h5>Board to expand to seven directors, with four Pure Capital nominees</h5><p>Under the settlement, directors Dr. Yael Margolin and Mr. Yoshinori Oikawa have resigned and will be replaced by Pure Capital nominees Dr. Adi Zuluf-Shani and Mr. Oz Adler. Evogene will convene a general shareholder meeting within 42 days of execution to formally elect the two nominees, ratify the agreement's waivers and non-disparagement terms, and approve two further Pure Capital nominees, Mr. Itay Maroz and Mr. Shahar Zadok, who will replace outgoing directors Mr. Dan Falk and Dr. Adrian Percy. Once approved, the reconstituted board will hold seven seats: four controlled by the Pure Capital Group and three continuing directors — Mr. Ofer Haviv, Mr. Nir Nimrodi, and Mr. Leon Y. Recanati — who will serve through a transition period expected to last up to six months.</p><h5>Pure Capital withdraws tender offer notice, accepts 60-day standstill</h5><p>The Pure Capital Group has agreed to formally withdraw its special tender offer notice and enter a 60-day standstill period. During this window, Evogene has committed to refrain from issuing new shares or convertible securities, including through its at-the-market facility, except for standard employee issuances in the ordinary course of business.</p><h5>Settlement clears path for ChemPass AI commercialization focus</h5><p>Evogene's board unanimously determined the agreement serves shareholder interests by avoiding a prolonged legal battle over the tender offer. The company stated the resolution allows it to concentrate on its generative AI platform, ChemPass AITM, and ongoing commercial collaborations in small-molecule drug and ag-chemical discovery.</p>", "meta_description": "Evogene settles board dispute with Pure Capital Group, averting a hostile tender offer and expanding its board to seven directors under a new cooperation pact.", "seo_keywords": "Evogene, Pure Capital Group, EVGN, ChemPass AI, tender offer, board dispute, Israeli Companies Law, shareholder agreement", "companies": ["Evogene Ltd.", "L.I.A. Pure Capital Ltd.", "Invest Pro Shukai Hon Ltd."], "industries": ["Biopharmaceuticals"], "markets_regions": ["Middle East & Africa", "Global"], "news_type": ["regulatory_update", "general_news"], "themes": ["corporate_governance", "regulatory_compliance"], "products": ["ChemPass AI"], "events": [], "cta_text": "Follow Evogene's board restructuring and governance resolution with the Pure Capital Group.", "learn_more": "https://www.evogene.com", "fact_check": {"accuracy_score": 100, "legal_risk": "low", "corrections_made": [], "recommendation": "publish"}}
Content Hash (SHA-256, erste 32 hex)
fcec321d6e615d6b6f7f39f999bd7a95
ZIM Raises Full-Year 2026 Guidance
Image File
Original HTML

Midpoint of updated full year guidance represents an increase of 30% in

Adjusted EBITDA and 72% in Adjusted EBIT compared with previous guidance

HAIFA, Israel, Oct. 6, 2026 /PRNewswire/ -- ZIM Integrated Shipping Services Ltd. (NYSE: ZIM) (the "Company" or "ZIM") today raised its guidance for the year ending December 31, 2026, reflecting continued strong market demand and favorable momentum in freight rates.

ZIM now expects to generate Adjusted EBITDA of between $2.7 billion and $3.0 billion and Adjusted EBIT of between $1.4 billion and $1.7 billion for the full year 2026, compared with its previous guidance of Adjusted EBITDA between $2.0 billion and $2.4 billion and Adjusted EBIT between $700 million and $1.1 billion.

The midpoint of the updated full year 2026 guidance represents an increase of 30% in Adjusted EBITDA and 72% in Adjusted EBIT compared with previous guidance provided on August 19, 2026.

About ZIM

Founded in Israel in 1945, ZIM (NYSE: ZIM) is a leading global container liner shipping company with operations in more than 90 countries, serving over 30,000 customers across more than 300 ports worldwide. ZIM leverages digital strategies and a commitment to ESG values to provide customers innovative seaborne transportation and logistics services and exceptional customer experience. ZIM's differentiated global-niche strategy, based on agile fleet management and deployment, covers major trade routes with a focus on select markets where the company holds competitive advantages. Additional information about ZIM is available at www.ZIM.com.

Forward-Looking Statements

This press release contains, or may be deemed to contain, forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties, assumptions, and other important factors, may include statements regarding macroeconomic and geopolitical conditions, chartering agreements, anticipated capacity, and the timing thereof, statements relating to the timing and closing of the pending transaction with Hapag-Lloyd, the Company's anticipated growth strategies and anticipated trends in its business. These statements are only predictions based on the Company's current expectations and projections about future events or results. There are important factors that could cause the Company's actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Factors that could cause such differences include, but are not limited to: our expectations regarding general market conditions as a result of the current geopolitical instability, developments and further escalation of events, including, but not limited to, risks and uncertainties relating to outcome of the pending transaction with Hapag-Lloyd, the current military conflict between Israel and the U.S. against Iran and some of its proxies, the Houthi attacks against vessels in the Red Sea, the war between Israel and Hamas, Iran and Iranian-backed proxies (including its impact on the Strait of Hormuz), the political and military instability in the Middle East and the war between Russia and Ukraine; our expectations regarding general market conditions as a result of global economic trends, including potential rising inflation and interest rates as a result of geopolitical and other events; our expectations regarding trends related to the global container shipping industry, including with respect to fluctuations in vessel and container supply, industry consolidation, demand for containerized shipping services, bunker and alternative fuel prices and supply, charter and freight rates, container values and other factors affecting supply and demand; our plans regarding our business strategy, areas of possible expansion and expected capital spending or operating expenses; our ability to adequately respond to political, economic and military instability in Israel and the Middle East (particularly as a result of the Israel-Hamas war and the Israel-Hezbollah and Israel-Iran armed conflicts), and our ability to maintain business continuity as an Israeli-incorporated company in times of emergency; our ability to effectively handle cyber-security threats and recover from cyber-security incidents, including in connection with the war between Israel and Iran and Iranian-backed proxies; our anticipated ability to obtain additional financing in the future to fund expenditures; our expectation of modifications with respect to our and other shipping companies' operating fleet and lines, including the utilization of larger vessels within certain trade zones and modifications made in light of environmental regulations; the expected benefits of our cooperation agreements and strategic partnerships; formation of new alliances among global carriers, changes in and disintegration of existing alliances and collaborations, including alliances and collaborations to which we are not a party to; our anticipated insurance costs; our expectations regarding the availability of crew; our expectations regarding our environmental and regulatory conditions, including extreme weather events (such as the drought conditions in the Panama Canal), changes in laws and regulations or actions taken by regulatory authorities, and the expected effect of such regulations; our expectations regarding potential liability from current or future litigation; our plans regarding hedging activities; our ability to pay dividends in accordance with our dividend policy; our expectations regarding our competition and ability to compete effectively, and other risks and uncertainties detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission (SEC), including under the caption "Risk Factors" in its 2025 Annual Report filed with the SEC on March 9, 2026 and its Notice and Proxy Statement attached as Exhibit 99.1 to its Current Report filed with the SEC on March 19, 2026 in connection with the pending transaction with Hapag-Lloyd.

Although the Company believes the expectations reflected in the forward-looking statements contained herein are reasonable, it cannot guarantee future results, level of activity, performance or achievements. The Company assumes no duty to update any of these forward-looking statements after the date hereof to conform its prior statements to actual results or revised expectations, except as otherwise required by law.

The Company prepares its financial statements in accordance with IFRS Accounting Standards (IFRSs), as issued by the International Accounting Standards Board (IASB).

Use of Non-IFRS Financial Measures

The Company presents non-IFRS measures as additional performance measures as the Company believes that it enables the comparison of operating performance between periods on a consistent basis. These measures should not be considered in isolation, or as a substitute for operating income, any other performance measures, or cash flow data, which were prepared in accordance with IFRS as measures of profitability or liquidity. Please note that Adjusted EBITDA does not take into account debt service requirements or other commitments, as well as capital expenditures, and therefore, does not necessarily indicate the amounts that may be available for the Company's use. In addition, the non-IFRS financial measures presented by the Company may not be comparable to similarly titled measures reported by other companies due to differences in the way these measures are calculated.

Adjusted EBITDA is a non-IFRS financial measure which we define as net income (loss) adjusted to exclude financial expenses (income), net, income taxes, depreciation and amortization in order to reach EBITDA, and further adjusted, as applicable, to exclude impairment of assets (or the reversal of which), capital gains (losses) beyond the ordinary course of business, expenses related to legal contingencies and acquisition related expenses (compensation costs and professional fees).

Adjusted EBIT is a non-IFRS financial measure which we define as net income (loss) adjusted to exclude financial expenses (income), net and income taxes, in order to reach our results from operating activities, or EBIT, and further adjusted, as applicable, to exclude impairment of assets (or the reversal of which), capital gains (losses) beyond the ordinary course of business, expenses related to legal contingencies and acquisition related expenses (compensation costs and professional fees).

Adjusted Net Income is a non-IFRS financial measure which we define as net income (loss) adjusted, as applicable, to exclude impairment of assets (or the reversal of which), capital gains (losses) beyond the ordinary course of business, expenses related to legal contingencies and acquisition related expenses (compensation costs and professional fees), all of which net of their respective income tax effect.

Free cash flow is a non-IFRS financial measure which we define as net cash generated from operating activities minus capital expenditures, net.

Net debt is a non-IFRS financial measure which we define as face value of short- and long-term debt, minus cash and cash equivalents, bank deposits and other investment instruments.

Net cash position is a non-IFRS financial measure which we define as the total cash position (which includes cash and cash equivalents, bank deposits and other investment instruments) minus financial debt (i.e., excluding lease liabilities).

Class (B2B/B2C)
B2B
Ingest Status
Need Review
Dedupe hash
prn_302900194
Press Eligible
Yes
Press Eligible Reason
QA FAIL (need review): TARGET contains unsupported factual claims: it calls the upgrade the 'second guidance hike of the year' when the SOURCE only mentions a previous guidance without stating it was the first, and it attributes the raise to 'tighter vessel capacity' while the SOURCE cites only strong market demand and favorable freight-rate momentum.
Source Name
Unknown Company
Original Summary

<p>Midpoint of updated full year guidance represents an increase of 30% in Adjusted EBITDA and 72% in Adjusted EBIT compared with previous guidance HAIFA, Israel, Oct. 6, 2026 /PRNewswire/ -- ZIM Integrated Shipping Services Ltd. (NYSE: ZIM) (the "Company" or "ZIM") today raised its guidance...</p>

Image URL
https://mmx.prnewswire.com/media/MS1018444/ZIM-Logo.jpg?id=OA2990590&p=facebook
Generated Article_json
{"target_audience": "b2b", "is_medical": false, "ai_generated_title": "ZIM Raises 2026 Guidance, Adjusted EBITDA Seen Up 30%", "body_html": "<p><strong>Haifa -- [CURRENT_DATE] --</strong> ZIM Integrated Shipping Services has raised its full-year 2026 financial guidance, now projecting Adjusted EBITDA of $2.7 billion to $3.0 billion, up from a prior range of $2.0 billion to $2.4 billion. The Israeli container liner also lifted its Adjusted EBIT forecast to between $1.4 billion and $1.7 billion, compared with the previous outlook of $700 million to $1.1 billion issued on August 19, 2026.</p><h5>Midpoint guidance shows 30% EBITDA jump and 72% EBIT surge</h5><p>The midpoint of the updated 2026 guidance represents a 30% increase in Adjusted EBITDA and a 72% increase in Adjusted EBIT versus the company's prior projection. ZIM attributed the revision to continued strong market demand and favorable momentum in freight rates.</p><h5>Freight rate strength drives second guidance hike of the year</h5><p>The upgrade marks a sharp shift from the company's August outlook, reflecting tighter vessel capacity and sustained pricing power across its global network. ZIM operates in more than 90 countries, serving over 30,000 customers through more than 300 ports worldwide.</p>", "meta_description": "ZIM raises 2026 guidance, now projecting Adjusted EBITDA up to $3.0 billion and Adjusted EBIT up to $1.7 billion on strong freight rate momentum.", "seo_keywords": "ZIM, container shipping, EBITDA guidance, freight rates, Hapag-Lloyd, Adjusted EBIT, shipping industry, NYSE:ZIM", "companies": ["ZIM Integrated Shipping Services", "Hapag-Lloyd"], "industries": ["Transportation & Mobility"], "markets_regions": ["Middle East & Africa", "Global"], "news_type": ["financial_disclosure", "general_news"], "themes": ["supply_chain", "financial_performance"], "products": [], "events": [], "cta_text": "Learn more about ZIM's updated financial guidance and shipping operations", "learn_more": "https://www.ZIM.com", "fact_check": {"accuracy_score": 100, "legal_risk": "low", "corrections_made": [], "recommendation": "publish"}}
Content Hash (SHA-256, erste 32 hex)
163f7042aa6ab96806cb95559d6f893d
Strategic Buyer Acquires Florida MSP as Demand Rises for Managed IT Services
Image File
Original HTML

Deal Facilitated by Viking Mergers & Acquisitions

TAMPA, Fla., Oct. 6, 2026 /PRNewswire/ -- A managed IT and cybersecurity services provider serving small and mid-sized businesses in Florida has been acquired by a strategic buyer, bringing together complementary IT industry expertise and further building upon a platform for continued growth.

"Delivering outcomes like this for business owners is what drives our Florida team," said Larry Lawson II, President, Viking Florida Division. "Tripp, Jacob, and Dylan guided every step of this process and brought together a seller and buyer well-positioned for long-term success."

For over 15 years, the company has grown from a traditional Managed Services Provider (MSP) into a full Managed Security Services Provider (MSSP). Built as a business known for responsiveness, personalized service, and security solutions tailored to each client, much of the company's growth came through referrals and long-term client relationships, supported by an experienced team that manages day-to-day service delivery. The company's clients include non-profit organizations, law firms, and family-owned medical practices that rely on responsive, security-focused IT support.

The buyer is an established managed IT services provider with a multi-state footprint, already serving nonprofit, financial, and healthcare clients. Together, the shared focus on IT services and preserving the legacy of the companies they acquire created a strong strategic fit, positioning the business for continued growth in Florida and nationwide.

The transaction was facilitated by the Viking Mergers & Acquisitions team: Larry "Tripp" Lawson III, Partner, Jacob Middleton, Associate Partner, and Dylan Bradley, Associate Advisor, who represented the seller throughout the sale process. From engagement to close, the transaction took approximately six months, reflecting growing buyer demand for IT solutions companies in the lower-middle market.

"We ran a disciplined process, kept the right buyers at the table, and gave our client real choices. That's what made the difference here," said Tripp Lawson. "We're proud to have delivered a smooth transition for the seller, their team, and the company's clients."

About Viking Mergers and Acquisitions Florida Division

Viking Mergers & Acquisitions, with offices strategically located throughout Florida, supports business owners with annual revenues ranging from $2M to $250M. Viking offers complimentary business valuation services, ongoing valuation updates, and comprehensive exit planning and strategy for small and middle-market business owners.

As one of the largest and most successful mergers and acquisitions firms in the United States, Viking is headquartered in Tampa, FL, and Charlotte, NC. The firm has offices strategically positioned across the U.S., providing exceptional brokerage services as well as mergers & acquisitions advisory work. Over the past three decades, Viking has successfully sold over 950 businesses, achieving a closing ratio of nearly four times the industry average. Viking consistently maintains an impressive 85% closing rate, securing sellers an average of 96% of their asking price.

Visit https://www.vikingmerger.com to request a confidential, complimentary business valuation or to access more information regarding selling or buying a business.

SOURCE Viking Mergers & Acquisitions

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Rewritten
Dedupe hash
prn_302900302
Press Eligible
Yes
Press Eligible Reason
Reports the acquisition of a managed IT and cybersecurity services provider.
Source Name
Unknown Company
Original Summary

<p>Deal Facilitated by Viking Mergers & Acquisitions TAMPA, Fla., Oct. 6, 2026 /PRNewswire/ -- A managed IT and cybersecurity services provider serving small and mid-sized businesses in Florida has been acquired by a strategic buyer, bringing together complementary IT industry expertise and...</p>

Image URL
https://mmx.prnewswire.com/media/MS2003641/Florida-MSP-aquired-by-a-Stragic-Buyer.jpg?id=OA2990700&p=facebook
Content Hash (SHA-256, erste 32 hex)
f1686127f124e44445b07cb5fda6b0b7